Epidermal growth factor receptor mutation (EGFRm) has been proven as the predictive factor for EGFR tyrosine kinase inhibitors (EGFR-TKIs) treatment in advanced NSCLC with EGFRm. EGFR-TKIs are an effective treatment and provide a significant increase in survival and better quality of life in EGFRm advanced NSCLC patients [10, 11]. Here, EGFR is linked to non-small cell lung carcinoma.